NANO3D SYSTEMS LLC

NANO3D SYSTEMS LLC is a company formulating, marketing and selling proprietary specialty chemicals for metal deposition including Electroplating (EP), Electroless Plating (ELP), and Atomic Layer Deposition (ALD) for advanced electronics applications. This company is built upon many years of experience of industry veterans who are focusing on delivering high-­‐performance and high-­‐quality innovative plating materials at an attractive price. Their products are used for research and development as well as commercial scale applications, especially in microelectronic, transportation and chemical industries. They also provide custom formulations of plating solutions, precursor synthesis, micro-­‐fabrication and characterization services. NANO3D's electrochemical

technology is based on proprietary formulations of plating solutions with unique features a) superior chemistries enabling high speed plating; b) selective plating of fine features, and c) alloys with unique properties. The company need advanced plating enables next generation consumer and power electronic devices.

IntellaSphere

IntellaSphere is a company developing the world’s first Brand Affinity Marketing System. It is an integrated, all-­‐in-­‐one marketing platform which transforms marketing from a solitary to a socially collaborative approach by turning supporters into active promoters. IntellaSphere is digital marketing and their SaaS (software as a service) platform eliminates the need for multiple marketing tools and presents an immediate positive ROI for marketers and businesses, saving them time and money, while improving their marketing effectiveness. In addition, they also offer marketing service for additional 'hands-­‐on' marketing assistance, which is delivered by their hybrid

on-­‐shore / off-­‐shore marketing services team with its growing network of certificated marketing partners. IntellaSphere’s success is to helps Harness the Power of Grass-­‐Roots Brand Advocates to Amplify the Success of Key Marketing Initiatives. Currently, they are in growth stage with realistic breakeven in 16 months with strong, experienced, proven management team.

Enlyte

Enlyte was founded to provide a stigma-free, digital therapeutic platform to help reduce the estimated $560 Billion of cost in lost workforce productivity in the US alone due to stress, anxiety, depression and addiction. 90% of the people that urgently need help do not receive it, primarily due to stigma, out of pocket expenses, and treatment facility capacity issues, so the evolving digital therapeutics industry allows for exponential technology to reach and help many more people than currently possible. The Enlyte platform is based on Cognitive Behavioral Therapy (CBT) principles and was co-­developed with psychologists and neuroscientists from prominent mental health facilities from several countries, and is coupled with other components to form a holistic approach to the concept of obtaining and maintaining a healthy mind and healthy body.

optimize.health

optimize.health is a next-­‐generation remote patient monitoring platform. Our cloud-­‐based platform receives data from a range of wireless health devices, including cellular and

bluetooth-­‐based blood pressure cuffs, scales, glucometers, and smart medication packaging, with data being stored in easy-­‐to-­‐interpret reports that clinical teams (doctors, nurses, pharmacists, etc.) can use to identify which patients need proactive communication. Built-­‐in communication tools facilitate communication by the care team. This approach has  been shown to lead to reduced hospitalizations, reduced costs, and better health outcomes. Starting in 2019, our system became reimbursable by health insurance in the U.S., including Medicare. We have  features  built  into  the  product  that enable reimbursement to providers in a way that is compliant with U.S. regulations. During the next phase of the company we will create a network of integrations to Electronic Health Records and  apply  artificial  intelligence  techniques to our unique data source to create a very powerful clinical decision support tool that is  informed  by  realtime  data  from hundreds of thousands of patients. This dataset will be useful to creating better healthcare outcomes, both in the U.S. and globally.

Litesprite

Litesprite builds games to manage chronic health conditions.  Clinicians  can  use  their  data  to  remotely monitor patients, standardize care and documentation, receive reimbursement, and identify  high-­‐risk  individuals  to  prevent  adverse  events.  Their  games  gather  important,  hard-­‐to-­‐ collect,  in-­‐field  data  like  text,  image,  video,  and  voice,  that  can  be  used  to  construct  new  digital biomarkers. They develop to applying machine learning to our unique data sets, predictive models,such  as  first-­‐of-­‐kind  suicide-­‐risk  predictive  models.  Their  mental  health  video  game,  Sinasprite,  is  the  first  to  win  a  U.S. Surgeon General Award and the only one recommended by payers and clinics. It impacts many chronic conditions, including cancer and cardiovascular, and different parts of the patient journey. Sinasprite uses evidence-­‐based treatment methods,  including  cognitive-­‐behavioral-­‐therapy  (CBT)  and  mindfulness  strategies.  Their  disruptive  innovation  has  been recognized with 20 international health innovation awards, and their future business models include an outcomes-­‐based cost savings model.

Visom Technology

Visom is a healthcare data company that is starting with an AR app using the Microsoft HoloLens. Our application uses facial feature detection for identification of patient anatomy in order to overlay and align their 3D imagery from CT, MRI scans. The software uses geometric algorithms along with cutting edge machine learning and computer vision; the combination is very efficient and allows the app to run fully self-­‐contained within the HoloLens headset. Additionally, the software executes basic segmentation of medical images with image processing and
three-­‐dimensional visualization. Image-­‐guided surgery (IGS) enables a surgeon to use a patient’s pre-­‐operative imaging data (such as CT or MRI) as a real-­‐time reference during a procedure; it basically shows the surgeon the spot on the scan image that is associated with the pointer instrument tip location. IGS is limitedto only 20% of surgical procedures. Studies have shown that IGS can improve accuracy by 2X and reduce reoperation rate by 66%-­‐100% for select procedures. The reason why devices with such promise have so little adoption is a combination of technical limitations and poor user experience. Lagging adoption decreases patient access to best care, and outdated technology wastes surgeons’ and patients’ time. Lack surgeon time is the larger backdrop in front of which this specific technological problem sits. The anticipated physician shortage and rising burnout rate only amplifies these harms to patient and surgeon.